Tempus AI stock gains more than 10% after first adjusted profit and expanded collaborations

Traders Union
All News
Stocks
Tempus AI surges 10.28% today

Highlights

Tempus AI revenue rose 23% year over year to $411.5 million, reaching its first adjusted quarterly profit with $25.6 million in adjusted EBITDA.
Full-year 2026 revenue guidance increased to $1.60 to $1.605 billion, with new pharma collaborations and the Personalis acquisition expanding the precision medicine portfolio.
Shares of Tempus AI gained 10.28% to $79.8, trading above key averages, with a five-day expected range of $74.13 to $85.79 and a 65% probability of further upside.

Oncology growth and partnerships drive guidance hike and profit turnaround

Tempus AI reported strong financial results for the third quarter of 2026, with revenue increasing 23% year-over-year to $411.5 million, driven by growth in oncology diagnostics and data services. The company achieved its first adjusted profit, delivering $25.6 million in adjusted EBITDA and narrowing its net loss to $14.9 million, aided in part by unrealized gains on marketable securities. Guidance for full-year 2026 revenue was raised to $1.60–$1.605 billion, with adjusted EBITDA forecast steady at approximately $65 million. Additional catalysts include expanded collaborations with pharmaceutical companies such as Bristol Myers Squibb, Merck, and Moderna, and the announced acquisition of Personalis to grow its AI-enabled precision medicine portfolio.

Anton Kharitonov, expert at Traders Union, notes the sharp price rise but urges caution given the overbought technical signals. He points out mixed momentum as a warning, with both the MACD and ADX failing to confirm bullish conviction. The analyst is skeptical about sustainability, highlighting substantial volatility and overextension above moving averages. While the quarter's partnership news is positive, he questions how much is already priced in. "Short-term buyers may dominate now, but I see real risk if the price breaks below $78.34 — aggressive chasers should beware."

Viktoras Karapetjanc, expert at Traders Union, sees strong foundations supporting Tempus AI’s bullish trajectory. He highlights the double-digit revenue growth, first adjusted profit, and strategic partnerships as clear signals of business momentum. The analyst believes the raised guidance and recent acquisition unlock further upside potential. He remains confident in the stock’s ability to consolidate at higher ranges and attract institutional flows. "With the bullish structure intact and pharma deals ramping up, I see further growth and new market setups ahead for Tempus AI."

Jainam Mehta, market strategist, observes that the price action is robust but faces possible pullback risk from diverging short-term indicators. He sees the wide volatility band and oscillator divergence as an opportunity for tactical entries. The analyst notes that a breakout above $83.27 could bring fresh momentum, while a drop below support would favor mean reversion trades. "Traders should watch for directional bias shifts near $83.27 and $78.34 — tactical setups may emerge as this volatility band resolves."

Session highs and overbought signals as momentum indicators diverge

Tempus AI is currently trading at $79.8, positioned above all key moving averages: $70.14 (MA-20), $70.68 (MA-50), and $56.94 (MA-200), which signals sustained bullish pressure across short-, medium-, and long-term trends. The near-term ceiling sits at $83.27, with support at the near-term floor of $78.34; the Ichimoku Kijun ($75.11) also underpins the price action from below. Momentum signals are mixed: the MACD and Average Directional Index (ADX) both remain neutral, but the Relative Strength Index (RSI) suggests a buy, and the Commodity Channel Index (CCI) also indicates upward bias. The Stochastic RSI issues a strong sell warning, creating divergence among oscillators. Bull/Bear Power (BBP) at 5.4 shows intraday dominance by buyers and flashes an overbought condition. Daily performance is strong, with the stock gaining $7.44 or 10.28%, following an upside gap of $1.65 (2.28%); the current price is near the day's high, and intraday volatility stands at 17.50%. The session tone reflects sustained buying pressure toward session highs, partially at odds with some overbought oscillators.

Earlier, analysts noted that despite robust long-term growth prospects, Tempus AI was contending with persistent short- and medium-term selling pressure even after positive earnings reports. The latest results, accompanied by a strong technical breakout and expanded pharma partnerships, add significant momentum to the bullish scenario, making $83.27 a critical level to watch for a potential upside move in the coming sessions.

Source of Data: TEM Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.